Third-quarter net income fell 20.4% to $2.43B, with diluted EPS of $1.94.

Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 7, 2025 · ~1 min read

Key Changes

• medium

  The Board declared a quarterly dividend of $0.82 per share in October 2026, up from $0.82 declared in the third quarter.

  view on EDGAR →
• medium

  Gilead received FDA approvals for Bixlenvo in HIV, Hepcludex in HDV, and Trodelvy in first-line mTNBC, and completed acquisitions of Arcellx, Tubulis and Ouro Medicines.

  view on EDGAR →
• medium

  Acquired in-process research and development expenses fell 89.4% to $18.0M in the quarter and rose 2231.3% to $11.31B for the nine months; all of the $10.82B increase came before the quarter.

  view on EDGAR →